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Abstract  
Background: Oral anticoagulant therapy is conditioned by environmental and genetic factors. 
Objectives: To verify the effect of the calumenin, cytochrome P-450 variants and VKORC1 genetic 
polymorphisms on the response to warfarin therapy and warfarin dose adjustment. 
Patients and Methods: We selected fifty warfarin treated patients with dose adjusted at INR value 
between 2 and 3. PCR-RFLP is used for of calumenin gene polymorphism. Insitu Hybridization was 
used for identification of VKORC1 promoter and CYP2C9 variants polymorphisms. 
Results: The warfarin dose in the patients with Calumenin and CYP2C9 genetic polymorphism was 
lower than the wild type gene. The warfarin dose in the patients with VKORC1 variants was 
statistically lower compared to that of the wild-type. The presence of combined CYP2C9 genetic 
variants and VKORC1 polymorphism was associated with lower warfarin dose than that the wild 
types. 
Conclusion: Calumenin (CALU) might be a new genetic factor involved in the pharmacogenetics of 
anticoagulant therapy.  
 
 
 
 
 
 
Introduction 
The vitamin K-dependent γ-carboxylation 
system is a multicomponent system of integral 
membrane proteins and lipids located in the 
endoplasmic reticulum (ER) [1]. This system modifies 
vitamin K-dependent proteins post- translationally by 
adding an extra carboxyl group to allow calcium 
binding [2, 3]. In the blood coagulation system, seven 
proteins produced by the liver (prothrombin, factors 
VII, IX, and X, protein S, protein C, and protein Z) are 
dependent on this modification [2]. 
The vitamin K-dependent γ-carboxylation 
system (VKOR) consists of 1) the vitamin K-
dependent γ-carboxylase, which requires the reduced 
hydroquinone form of vitamin K1 (vit.K1H2) as 
cofactor, and 2) the warfarin-sensitive enzyme vitamin 
K1 2, 3-epoxide reductase (VKORC1), which 
produces the cofactor. Concomitant with γ- 
carboxylation, the hydroquinone is converted to the 
metabolite vitamin K1 2, 3-epoxide, which is reduced 
back to the vit.K1H2 cofactor by VKOR [4]. This 
interconversion of vitamin K metabolites is known as 
the vitamin K cycle [3]. 
Warfarin is the most widely prescribed 
anticoagulant used for thromboembolic therapy [5]. 
Warfarin functions as a vitamin k antagonist and thus 
inhibits the activity of vitamin K-dependent 
coagulation proteins by inhibiting vitamin K epoxide 
reductase [6]. It is used for treatments of many health 
conditions, including arterial fibrillation, deep vein 
thrombosis, and recurrent stroke [7]. Large 
interindividual differences exist in warfarin dose 
requirements, which present challenges in its 
management. Warfarin dose requirements are 
influenced by ethnicity, age, gender, body mass index 
(BMI), and concurrent use of other medication [8]. 
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In addition several studies have revealed genetic 
components that influence the dose of warfarin 
necessary for a therapeutic response. 
A polymorphism within the promoter region of 
VKORC1 gene, encoding the subunit 1 of the vitamin 
K epoxide reductase complex; the target of warfarin, 
specifically a guanine to adenine conversion at 
position −1639 (−1639 G>A, rs9923231), decreased 
production of VKORC1 mRNA and reduced 
expression of the enzyme [9]. 
Cytochrome P-450 2C9 is the principle 
enzyme that terminates the anticoagulant effect of 
warfarin.  Genetic polymorphisms  in  CYP2C9  
producing  variants  with  altered  catalytic  properties  
have  been  identified  [10].  In addition to the wild-
type CYP2C9*1 allele, 2 allelic variants, cytosine-to-
thymine transversion at nucleotide 430 encodes for a 
cysteine substitution at amino-acid residue 144, 
producing the CYP2C9*2 variant allele. An adenine- 
to-cytosine transversion at nucleotide 1075 encodes 
for a leucine substitution at amino-acid residue 359, 
producing the CYP2C9*3 variant allele, with 
approximately 12% and 5% enzymatic activity, 
respectively, have been identified [11]. Due to an 
impaired metabolic capacity, patients having at least 
one CYP2C9*2 or CYP2C9*3 allele require, on 
average, a lower dose of anticoagulant than 
homozygotes for the CYP2C9*1 allele [12]. 
Calumenin (CALU) is a calcium-binding 
protein localized in the endoplasmic reticulum (ER) 
[13]. The chaperone CALU appears to regulate the 
capacity of the vitamin K-dependent γ-carboxylation 
system [1, 14, 15]. Binding to VKOR will prevent 
warfarin from reaching its binding site on VKOR and 
thus produce resistance to the drug. 
Variants in these genes affect warfarin dose 
requirements at steady state substantially [16, 17]; 
moreover, at the start of warfarin therapy, VKORC1 
and, to a lesser extent, CYP2C9 genotypes also 
affect early INR responses [18]. The clinically useful 
contribution of genotype to individualizing warfarin 
dose will probably be greatest in the initiation phase 
of therapy, before a person’s dose requirement has 
been determined empirically by titration according to 
INR response [19]. 
The US Food and Drug Administration [20] 
included with warfarin product labeling consideration 
of CYP2C9 and VKORC1 genotypes for optimizing 
warfarin dosing schedules. Use of genetic biomarkers 
could reduce the time needed to attain 
anticoagulation target levels, thereby reducing the 
incidence of adverse effects, but the optimal SNP for 
genotyping remain uncertain. 
The main purpose of this study was to 
analyze genetic polymorphisms of calumenin gene 
(Arg4Gln), cytochrome P- 450 gene; CYP2C9*2 and 
*3 variants, and VKORC1 promoter gene (-1639 
G>A) with special attention to the role of calumenin 
gene polymorphism (Arg4Gln)   as a new marker in 
monitoring warfarin therapy and  correlated the 
presence of this polymorphism together with the 
previously studied cytochrome P-450 gene; 
CYP2C9*2 and *3 variants, and VKORC1 promoter 
gene polymorphism (-1639 G>A) to determine if the 
combination between the three polymorphisms 
changed the required dose in patients treated with 
warfarin oral anticoagulant for certain indications. 
 
Subjects and Methods 
Study population 
The present study was conducted on 50 
patients [38 patients with valvular heart disease; 
mitral and tricuspid valve regurge, 6 patients with 
atrial fibrillation (AF) and 6 patients with deep venous 
thrombosis (DVT)] receiving warfarin therapy who 
regularly took a steady maintenance warfarin dose for 
at least one month provided that dose is adjusted at 
which INR value is between 2 and 3. Patients who 
currently took oral amiodarone or anti- inflammatory 
agents (i.e. NSAIDs or steroid) at the time of the 
present study were excluded. They were enrolled 
from the outpatient clinic of internal medicine and 
cardiology at Kasr El-aini hospital, Cairo University. 
The age of the patients ranged from 25 to 65 years 
old, with a mean ± 2SD of 44.8 ± 11.7, they were 18 
males (36%) and 32 females (64%). Their body mass 
index ranged from 20-24. Informed required 
consents were obtained from all participants in 
advance. The study was approved by the Scientific 
and Ethical Committees of Faculty of Medicine, Cairo 
University.   Patients with hypertension, liver disease, 
heart failure and malignancy were excluded from the 
study. Routine laboratory investigations included 
complete blood picture, ESR, coagulation profile; 
prothrombin time, concentration and INR, chemistry; 
liver function tests, random blood sugar, lipid profile 
and LDH. 
 
Sampling 
Three ml peripheral venous blood was 
withdrawn in sterile vacutainer tubes containing 
EDTA under aseptic precautions. The samples were 
stored at -20
0 C until DNA extraction. 
 
DNA extraction 
For all participants, genomic DNA was 
extracted from peripheral blood leucocytes using 
Promega Genomic DNA purification kit” (Promega 
Corporation, WI, USA). 
 
Genotyping for the calumenin 
CALU Arg4Gln polymorphism (rs 2290228) 
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was performed by PCR using the following primers 
(Operon Biotechnologies GmbH, Germany): Forward 
5`-GCT TTT CAT TTT CTT CAA G- 3`(location 9192-
9210) and 5`- GAC CCC TGA GAG GTG GTA CC-3` 
(location 9485-9266), the PCR product is then 
digested with HpyCH4 V restriction enzyme (Operon 
Biotechnologies). 
The Arg4 allele showed a restriction pattern of 
207 and 68 bp while the Gln4 allele yielded 207, 39 
and 29 bp. Reaction were performed in a total 
volume of 25 l as Nan et al., 2001 [21] described, 
12.5l of 2 x PCR Master Mix (Fermentas Life 
Sciences) 1l of forward primer, 1l reverse primers, 
2 l template DNA and completed with 8.5 l water, 
nuclease-free. The following PCR protocol was used: 
initial denaturation at 95
O 
C for 10 minutes, 30 cycles 
at 95
O 
C for 45 seconds, 50
 O
 C for 45 seconds and 
72
 O
 C for 45 seconds and a final extension step at 
72
O
 C for 3 minutes. 
After generation of PCR product, HpyCH4 V 
restriction enzyme   was added and incubated at 37
O 
C overnight, followed by detection of PCR 
amplification product by capillary electrophoresis, the 
bands of separation were detected using the 
automated QIAxcel system (Qiagen, USA) at Clinilab 
company, Egypt (Fig. 1). 
 
Figure 1: Results of PCR-RFLP analysis of Calumenin gene in 
samples from Warfarin treated patients, detected by QIAxcel 
instrument at Clinilab Company. The QX DNA size marker is 25-450 
bp and the QX Alignment marker is 15bp/500bp. Cases No. 1, 2, 3, 
4, 5, 6 and 11 have wild-type gene. Cases No. 7, 8, 10 and 12 are 
heterozygous for Arg4Gln polymorphism. Case No. 9 is 
homozygous for the polymorphism. 
 
PGX-Thrombo-strip assay 
Previously extracted genomic DNA samples 
were used in single multiplex PCR for amplification 
of relevant VKORC1 and CYP2C9 gene sequences, 
hybridization of biot inylated PCR products to 
oligonucleotide probes on the test strip, and finally 
detection of specifically bound mutant and wild-type 
alleles by visible enzymatic color reaction (Promega 
Corporation, Madison, WI USA) (Fig.2). 
 
 
Figure 2: Results of PGX-thrombo stripassay analysis of Cyp2c9 
and VKORC1 genes in samples from Warfarin treated patients. 
Regarding Cyp2c9 gene: cases No. 1, 6, 8, 11, 12, 17, 18 and 19 
have wild-type Cyp2c9 gene; cases No. 5, 16 and 20 are 
heterozygous for Cyp2c9*2 allele; cases No. 3, 4, 7, 13 and 14 are 
heterozygous for Cyp2c9*3 allele; cases No. 9, 10 and 15 are 
double heterozygous for Cyp2c9*2 & 3 alleles. Regarding 
VKORC1gene: case No. 7 has wild-type gene; cases No. 1, 2, 3, 
5, 8, 11, 12, 17 and 19 are homozygous for common 
polymorphism (-1639 G>A) in the VKORC1 promoter; cases  No. 
4, 6, 9, 10, 13, 14, 15, 16, 18 and 20 are heterozygous for this 
polymorphism. 
 
 
Statistical methods 
Data was analyzed using SPSS win statistical 
package version 17 (SPSS Inc., Chicago, IL). 
Numerical data were expressed as mean and 
standard deviation or median and range as 
appropriate. Qualitative data were expressed as 
frequency and percentage. 
Chi-square test (Fisher’s exact test) was used 
to examine the relation between qualitative variables. 
For quantitative data, comparison between two 
groups was done using Mann-Whitney test (non 
parametric t-test). Comparison between 3 groups 
was done using Kruskal-Wallis test (non-parametric 
ANOVA) then post-Hoc "Schefe test" on rank of 
variables was used for pair-wise comparison. A p-
value < 0.05 was considered significant. 
 
Results 
Descriptive data of the patients 
The present study included 50 middle aged 
patients receiving warfarin therapy for valvular heart 
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diseases, AF and DVT. The received doses given to 
adjust INR values between 2 and 3 were ranging 
from 2 to 20 mg/dl, median 6.5mg/dl (m e a n ± SD ═ 
6.95 mg/dl ± 3.76). The range of treatment duration 
was from 2.5 months to 22 years; median 10 years 
(mean ± SD ═10.54 ± 6.48 years). 
 
Genetic polymorphisms of the patients 
Results of genotyping of all patients are 
summarized in Table 1. No statistical significant 
differences could be detected between age and sex 
of patients with CYP2C9, Calumenin, or 
VKORC1genetic polymorphism and those carrying  
the  wild  types  (p  value  for  age  differences = 
0.946, 0.373, 0.769, respectively)  and  (p  value  for  
sex differences = 0.869, 0.233, and 0.283, 
respectively). 
Table 1: CYP2C, Calumenin and VKORC1 Genotypes frequency 
and distributions. 
Genotypes 
Frequency  
(n = 50) 
Percent (%) 
CYP2C9 
Heterozygous*1/*2 
Heterozygous*1/*3 
Heterozygous*2&3 
Homozygous*1/*1 
 
Calumenin gene  
Homozygous Glu/Glu  
Heterozygous Arg/Glu  
Homozygous Arg/Arg 
 
VKORC1 gene  
Homozygous AA  
Heterozygous AG  
Homozygous GG  
 
Combined  genes 
VKORC1 (AA,GA),CYP2C(*2/*3,*1/*2,*1/*3), Calumenin 
(Glu/Glu,Arg/Glu) 
VKORC1 (AA,GA),CYP2C(*2/*3,*1/*2,*1/*3) 
VKORC1 (AA,GA), Calumenin (Glu/Glu,Arg/Glu)  
CYP2C (*2/*3,*1/*2,*1/*3),Calumenin (Glu/Glu,Arg/Glu) 
 
 
7 
11 
9 
23 
 
 
3 
15 
31 
 
 
6 
40 
4 
 
 
 
9 
14 
12 
1 
 
14 
22 
18 
46 
 
 
6 
32 
62 
 
 
12 
80 
8 
 
 
 
18 
28 
24 
2 
 
The mean warfarin doses of the patients with 
Calumenin genetic polymorphism was not statistically 
significant in comparison to patients with the wild 
genotype (p value = 0.135). However the mean 
maintenance doses in patients with Calumenin gene 
polymorphism was 82.2% of that in wild-type gene. 
The mean maintenance doses in patients with 
CYP2C9 variant alleles was 78% of that in wild- type 
patients and this difference was almost statistically 
significant (p value = 0.050). 
The mean maintenance doses in patients with 
VKORC1 (AA, GA) polymorphism was 67% of that in 
wild-type, and this difference was statistically 
significant (p value = 0.044). 
The present study revealed that the presence 
of combined CYP2C9 genetic variants and VKORC1 
polymorphism (-1639 G>A) was associated with lower 
warfarin dose than the wild types. The mean dose for 
the combined CYP2C9 variants and VKORC1 (GA 
and AA) polymorphisms was 6.13 mg/dl ± 4 
comparing to 7.83 mg/dl ± 3.35, which is 78.2% of 
the wild types, and this difference was statistically 
significant (p value = 0.042). 
The mean dose of warfarin in patients with 
the combined 3 genetic polymorphisms was 4.89 
mg/dl ± 3.3, while in patients with wild type genes the 
mean dose was 10 mg/dl ± 1. Despite, significant 
relationship between the 3 polymorphisms couldn’t be 
detected due to small number of samples within the 
groups; however the mean of warfarin dose in cases 
of combined 3 polymorphisms is lower than the mean 
dose for the combined wild types. The mean 
maintenance dose in patients with the polymorphic 
genes was 48.9% of those carrying wild type genes 
(Table 2). 
Table 2:  Comparison between wild and polymorphic variants 
of CYP2C, Calumenin and VKORC1 Genes regarding 
demographic data and warfarin dose and duration. 
Polymorphism            Age                Sex          Warfarine duration          Warfarine dose 
                              (Mean±SD)      (M:F%)           (Mean± SD)                    (Mean± SD)                                                                                                                                        
CYP2C9                
Wild                       44.7 ± 11.7      44.4:46.9         8.79 ± 5.63                     7.85 ± 3.43                               
Polymorphic         44.8 ± 11.7      55.6:53.1       12.03 ± 6.88                    6.19 ± 3.93 
P-value                      0.946            0.869                   0.079                              0.05 
Significance                 NS                 NS                     NS                                    S       
 
VKORC1 
Wild                       42.8 ± 6.1              0:12.5       13.25 ± 5.68                    9.38 ± 1.49               
Polymorphic        44.9 ± 12.1       10.0:87.5      10.30 ± 6.55                     6.24 ± 3.83 
P-value                      0.769              0.283                     -                                  0.044   
Significance                NS                   NS                       -                                     S 
 
Caluminine 
Wild                      43.6 ± 11.2         50:68.8         10.58 ± 6.53                  7.45 ± 3.76 
Polymorphic        46.6 ± 12.6         50:32.2         10.47 ± 6.57                  6.13 ± 3.71        
P-value                     0.373                0.233                0.976                             0.135 
Significant                   NS                    NS                     NS                                  NS 
 
Combined 3 genes                                                                             
Wild                                                                      12.67 ± 6.81                       10 ± 1 
Polymorphic                                                         11.89 ± 6.81                     4.89 ± 3.3 
P-value                                                                           -                                      -               
Significance                                                                    -                                      - 
NS = Non significant; S=Significant. 
 
Warfarin intake duration in the patients with 
Calumenin genetic polymorphism mean was 10.47 
years ± 6.57, while in those with wild type gene was 
10.58 years ± 6.53. This differences was not 
statistically significant (p value = 0.976) 
Time to therapeutic INR was longer in 
CYP2C9 variant *2 and *3 alleles carrier patients 
compared to those with wild-type, and longer in 
patients with the VKORC1 (position -1639) GG 
genotype (wild type) compared with those with the 
GA genotype and the AA genotype, however, 
there was no statistical significant difference 
between duration of warfarin intake and polymorphic 
CYP2C and VKORC1 genotypes (p value = 0.079, 
0.98, respectively). 
 
Discussion 
Although no statistical significant difference 
was found regarding Calumenin (CALU) genotyping in 
the present study; the mean warfarin maintenance 
doses in patients with gene polymorphism was 82.2% 
of that in wild-type polymorphism. Similar to our 
results, Gonzalez-Conejero et al., 2007 genotyped 
100 patients from Murcia, Spain for CYP2C*9, 
VKORC1 and CALU Arg4Gln polymorphism. They 
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identified a homozygous CALU (Gln/Gln) patient; this 
patient reached a steady anticoagulation state with a 
low dose of oral anticoagulant [22]. 
On contrary to our results, Vecsler et al., 
2006 found one homozygous CALU (Gln/Gln) patient 
required a very high warfarin dose to achieve a steady 
INR (20 mg/ day) [16]. 
On other hand, Wadelius et al., 2007 failed to 
find any significant association between CALU 
Arg4Gln and warfarin dose requirements [23]. 
The present study revealed that the mean 
warfarin dose was lower in patients with CYP2C9 
genetic variants (6.19 mg/dl ± 3.93) than the mean in  
the wild type (7.85 mg/dl ± 3.43), with mean 
maintenance doses in patients with variant alleles 
was 78% of that in wild-type patients and this 
difference was almost statistically significant with a p 
value = 0.050. 
Our results were parallel to that of Hermida 
et al., 2002 in Spain, they stated that bearing the 
2C9*2 allele or the 2C9*3 allele was associated with 
the need for a lower acenocoumarol dose (odds 
ratio [OR], 2.70, 6.02; 95% confidence interval 
[CI], 1.11 -6.58, 1.50-24.18, respectively) [24]. Our 
results also were in agreement to Taube. et al., 2000 
[25] and Kamali et al.,2004 who demonstrated that 
the mean warfarin daily dose requirement in 
milligrams fell from 4.06 ±1.72 mg in homozygous 
CYP2C9 wild-type patients to 3.63 ±1.78 mg for 
*1/*2-positive patients and 2.70 1.36 mg for *1/*3-
positive patients [26].  
Ozer et al., 2010 reported that the mean 
warfarin daily dose requirement was higher in 
CYP2C9 homozygous wild-type patients, compared 
to those with the variant *3 allele (P < 0.05), similar 
to those with the variant *2 allele (P > 0.05) [27]. 
These results are also inconsistent with Sconce et al., 
2005 [28] and Miao et al., 2007, who stated that 
CYP2C9*1/*1 genotypes required a significantly 
higher warfarin dose than those with the -1639 AA (P 
< 0.001) or CYP2C9*1/*3 (P < 0.001), genotype [29]. 
Carlquist et al., 2006, also detected that warfarin 
doses varied by CYP2C9 genotype: with dose 
reductions of 18-31% for single and 82% for double 
variant carriers (P < 0.001) [30]. 
Regarding VKORC1 gene; the mean warfarin 
dose in the patients with VKORC1 (AA, GA) was 
lower (6.24 mg/dl± 3.83), than the mean warfarin 
dose with VKORC1 GG genotype (9.38 mg/dl ± 
1.49). The mean maintenance doses in patients with 
(AA, GA) polymorphisms was 67% of that in wild-type 
GG polymorphism, and this difference was statistically 
significant (p value = 0.044). In heterozygous group it 
was 7.25 mg/dl ± 3.82 and this differences was 
statistically significant with P value=0.014. 
Our study was in agreement to studies done 
by Yuan et al., 2005, Lee et al., 2006, Kimura et al., 
2007 and Wang et al., 2008  who all reported that the 
1639AA or 1173TT genotype of VKORC1 were 
consistently associated with lower warfarin dose 
requirements [9, 31-33]. Also the study by Wang et 
al., 2008 strongly favored 1639GA over 1173CT as 
the active polymorphism and that for optimal use of 
VKORC1 as a clinical biomarker for warfarin dose 
predictions, the 1639GA alone is sufficient [9]. 
Ozer et al., 2010 Carlquist et al., 2006, and 
Sconce et al., 2005, stated that the mean warfarin 
daily dose requirement was highest in patients with 
the VKORC1 -1639 GG genotype compared to those 
with the GA genotype and the AA genotype [27, 28, 
30]. stated that the mean warfarin daily dose requirement was highest in patients with the VKORC1 -1639 GG genotype compared to those with the GA genotype and the AA genotype [27, 30, 28]. 
The present study revealed that the mean 
warfarin dose in cases of combined 3 polymrphisms 
(4.82 ± 3.3) was lower than the mean dose for the 
combined wild types (10 ± 1). The mean maintenance 
dose in patients with the polymorphic gene was 
48.9% of the wild type genes. 
Concomitant to our results, Gonzalez-
Conejero et al., 2007 detected that carriers of the 
combined 3 polymorphic alleles were significantly 
more sensitive to therapy and they needed lower 
doses to stabilize their INR [22]. On the contrary, the 
study of Vecsler et al., 2006 revealed that CYP2C9 
andVKORC1 wild type and CALU mutant patients 
required the highest warfarin doses as compared to 
the CYP2C9 and VKORC1 mutant and CALU wild 
type genotypes. However compound genetic profiles 
comprising VKORC1, CALU and CYP2C9 improve 
categorization of individual warfarin dose 
requirements in more than 25% of patients at steady-
state anticoagulation [16]. 
The present study revealed no association 
between age (r=-0.270; P=0.056) and sex (P= 0.1) of 
the patients and warfarin dose requirements. In 
agreement with our results, Hermida et al., 2002, 
analyzed the effect of 2C9*3 and 2C9*2 variants, age, 
sex, and interacting drugs by using a multivariate 
ordered logistic regression model and detected that 
neither sex nor age affected the acenocoumarol 
anticoagulant requirement [24]. 
On the contrary, Sconce et al., 2005 
demonstrated that median warfarin daily dose 
requirements varied significantly with sex (2.9 mg 
females; 3.7 mg, males; P =.009). The warfarin 
doses was negatively correlated with age (r=0.40; P 
=0.001) [28]. 
Also, Kamali et al., 2004 demonstrated that 
the multiple linear regression model for warfarin dose 
indicated significant contributions of age (r = 0.41, P 
< .001), genotype (r = 0.24, P < .005), and age and 
genotype together (r= 0.45, P < .005) [26]. 
Similarly, Aquilante et al., 2006 and Oner 
Ozgon et al., 2008, stated that the variables 
associated with lower warfarin dose requirements 
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included increasing age (P < 0.0001) [34, 35]. 
The present study confirmed an association 
between CYP2C9 variants (*2, *3), VKORC1 (AA and 
GA) and CALU Arg/Gln polymorphisms and warfarin 
sensitivity, as the presence of one of this variant 
or 2 of them or the  combined  3  genetic profiles  
comprising VKORC1, CALU and  CYP2C9  improve  
categorization of individual warfarin dose 
requirements in patients at steady state 
anticoagulation. Also our results suggest that CALU 
a29809g might be a new genetic factor involved in the 
pharmacogenetics of anticoagulant therapy, although 
we didn’t find a significant relation so we try to enlarge 
our studies on calumenin polymorphism. 
The major complication of long-term oral 
anticoagulant is over-anticoagulation and bleeding. 
The risk of bleeding is associated  with  increasing  
INR  and  so  identification  of  genetic  and  
environmental  factors  that  predict  the development 
of a high INR might identify high-risk patients who 
would be candidates for more frequent monitoring or 
treatment with an alternative drug. As the 
pharmogenomics of warfarin-drug interactions is 
unraveled, genetic analysis may yet prove to have a 
role in the assessment of risk and management 
decisions relating to type of Anticoagulant, frequency 
of monitoring, and optimum duration of therapy. 
The main limitation of our study is the 
relatively reduced sample size. Confirmatory studies 
including large series of patients are necessary, 
where more complex profiles may also be evaluated 
in order to make oral anticoagulation a personalized 
therapy. 
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